Stocks and Investing
Stocks and Investing
Fri, August 21, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, August 20, 2020
[ 12:00 AM ] - WOPRAI
Martin Auster Downgraded (SRPT) to Hold and Decreased Target to $167 on, Aug 20th, 2020
Martin Auster of Credit Suisse, Downgraded "Sarepta Therapeutics, Inc." (SRPT) to Hold and Decreased Target from $185 to $167 on, Aug 20th, 2020.
Martin has made no other calls on SRPT in the last 4 months.
There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Martin's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Martin
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $182 on, Monday, August 10th, 2020
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $180 on, Wednesday, June 10th, 2020